See the powerful efficacy of ROCKLATAN®
(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
Once-daily ROCKLATAN® delivered
superior efficacy1
Study Designs
ROCKLATAN® was evaluated in 2 randomized, controlled clinical trials in patients with open-angle glaucoma and ocular hypertension, with baseline IOP <36 mmHg. These studies compared the IOP-lowering effect of ROCKLATAN® dosed once daily to individually administered netarsudil 0.02% once daily and latanoprost 0.005% once daily. The treatment durations for these studies were 12 months for MERCURY-1 and 3 months for MERCURY-2. The average IOP-lowering effect of ROCKLATAN® was 1 to 3 mmHg greater than monotherapy with either netarsudil 0.02% or latanoprost 0.005% throughout 12 months in MERCURY-1 and 3 months in MERCURY-2.2
For patients like Gary, consider ROCKLATAN® for powerful IOP reduction
PATIENT DETAILS*
• 67 years old
• Open-angle glaucoma with elevated IOP
• No comorbidities
PATIENT STATUS
• Gary has received selective laser trabeculoplasty in the past year and is currently taking latanoprost. He has reduced his IOP from 25 mmHg to 21 mmHg, but his ophthalmologist would like to aim for a target IOP of 19 mmHg
• He is concerned about adding another bottle to his regimen
TREATMENT PLAN
Consider replacing latanoprost with ROCKLATAN® for additional IOP lowering
IOP=Intraocular pressure;
mmHg=Millimeters of mercury.
REFERENCES
1. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.
2. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information. Aerie Pharmaceuticals, Inc., Irvine, CA. 2020.
3. Alcon data on file, 2022.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
- Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
- Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
- Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.
- Remove contact lenses prior to administration and reinsert 15 minutes after administration.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Adverse Reactions
The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Please click here for full prescribing information for ROCKLATAN® Solution.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.